Navigation Links
News from Molecular Medicine
Date:5/20/2010

Cystic Fibrosis (CF) continues to challenge scientists. There is growing evidence that increases in protease activity may be central to the pathogenesis of this lung disease. A team of scientists at the University of Alabama measured a common protease called MMP-9 in CF patients whose condition is stable and compared it with healthy volunteers. Previous studies have shown increases in MMP-9 in CF patients in the throes of an acute pulmonary episode. In the latest study, scientists at the University of Alabama in Birmingham reported that MMP-9 levels were also higher than normal in CF patients with no active airway inflammation. The findings may point the way to new therapeutic agents that work to reduce pathological changes.

Manhasset, NY (Vocus) May 20, 2010 -- In the latest issue of Molecular Medicine, cystic fibrosis (CF) continues to challenge scientists. There is growing evidence that increases in protease activity may be central to the pathogenesis of this lung disease. A team of scientists at the University of Alabama measured a common protease called MMP-9 in CF patients whose condition is stable and compared it with healthy volunteers. Previous studies have shown increases in MMP-9 in CF patients in the throes of an acute pulmonary episode. In the latest study, scientists at the University of Alabama in Birmingham reported that MMP-9 levels were also higher than normal in CF patients with no active airway inflammation. The findings may point the way to new therapeutic agents that work to reduce pathological changes.

In other studies in the latest issue of Molecular Medicine, a team of Brazilian scientists tested the activity of a novel angiotensin converting enzyme (ACE) in thrombus formation in animals that were either hypertensive or not. They reported that the pharmacological activation of the ACE2 receptor with the experimental ligand reduced platelet attachment to vessels and thrombus formation. These results suggest that this could be a potential lead compound for the treatment of thrombogenic diseases.

Other findings in the journal include a pivotal discovery of immune regulation of cancer cells, an endogenous factor that works in wound healing, a gene therapy study on Fabry Disease, a study on the immunological properties at work in Celiac disease, and a new molecular fingerprint of lung injury.

Molecular Medicine is published by The Feinstein Institute for Molecular Research. The peer-reviewed journal strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. The journal, a bimonthly publication, serves as a forum through which scientists and researchers can communicate recent discoveries to a multi-disciplinary, international audience interested in understanding and curing disease.

To listen to the latest podcast on these studies visit www.molmed.org/podcast.html.

###

Read the full story at http://www.prweb.com/releases/Molecular-Medicine/cystic-fibrosis/prweb4017864.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Molecular marker could help spot pancreatic cancer early
2. Molecular discovery points to new therapies for brain tumors
3. USC researchers discover new molecular subtype of brain cancer
4. The Association for Molecular Pathology celebrates ruling in DNA patent case
5. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
6. SNMs Conjoint Mid-Winter Meetings continue to advance molecular imaging
7. Molecular pathways linked to sex, age affect outcomes in lung cancer
8. Ground Breaking Molecular Diagnostics Business Appoints New CEO
9. Select Topics in ALL: Molecular Characterization, Approaches to CNS Disease, and Post-remission Transplantation
10. Scientists show how molecular switch helps pancreatic cancer beat drugs
11. News from the Latest Issue of Molecular Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
News from Molecular Medicine
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: